[Alendronate for treatment of osteoporoses].
Alendronate halves osteoporotic fractures in the spine regardless of the risk and in the proximal femur in the high-risk population. The long-term results are excellent, too. Concerning the safety, the risk of the bisphosphonate-associated osteonecrosis of the jaw is apparently low.
Department of Restorative Medicine, National Center for Geriatrics & Gerontology.
Atsushi
A
Harada
D019386:Alendronate / Q000008:administration & dosage* / Q000009:adverse effects; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019317:Evidence-Based Medicine; D005264:Femoral Fractures / Q000209:etiology / Q000517:prevention & control*; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced; D010020:Osteonecrosis / Q000139:chemically induced; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D012306:Risk; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*
D050071:Bone Density Conservation Agents; D019386:Alendronate